Sunil Kadam

Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report

Jean W. Lee, Russ S. Weiner, Jeff M. Sailstad et al. · Pharmaceutical Research · 2005 · 189 citations

Pharmacy, Pharmacology, Clinical Pharmacology +10

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

David S. Hong, Razelle Kurzrock, Yun Oh et al. · Clinical Cancer Research · 2011 · 131 citations · Full text

Medicine, Oncology, Pharmacology +17

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

Denis Talbot, Malcolm Ranson, J.N.P. Davies et al. · Clinical Cancer Research · 2010 · 98 citations

Medicine, Oncology, Pharmacology +17

5-N-Acetylardeemin, a novel heterocyclic compound which reverses multiple drug resistance in tumor cells. I. Taxonomy and fermentation of the producing organism and biological activity.

James P. Karwowski, MARIANNA JACKSON, Ronald R. Rasmussen et al. · The Journal of Antibiotics · 1993 · 98 citations · Full text

Medicine, Biochemistry, Pharmacology +11

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

Harry P. Erba, Hamid Sayar, Mark Juckett et al. · Investigational New Drugs · 2013 · 72 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14